Human Erythropoietin Gene Delivery Using an Arginine-Grafted Bioreducible Polymer System
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Youngsook | - |
dc.contributor.author | Nam, Hye Yeong | - |
dc.contributor.author | Kim, Jaesung | - |
dc.contributor.author | Lee, Minhyung | - |
dc.contributor.author | Yockman, James W. | - |
dc.contributor.author | Shin, Sug Kyun | - |
dc.contributor.author | Kim, Sung Wan | - |
dc.date.accessioned | 2022-04-01T09:56:57Z | - |
dc.date.available | 2022-04-01T09:56:57Z | - |
dc.date.created | 2022-01-24 | - |
dc.date.issued | 2012-05-16 | - |
dc.identifier.issn | 1525-0016 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/136487 | - |
dc.description.abstract | Erythropoiesis-stimulating agents are widely used to treat anemia for chronic kidney disease (CKD) and cancer, however, several clinical limitations impede their effectiveness. Nonviral gene therapy systems are a novel solution to these problems as they provide stable and low immunogenic protein expression levels. Here, we show the application of an arginine-grafted bioreducible poly(disulfide amine) (ABP) polymer gene delivery system as a platform for in vivo transfer of human erythropoietin plasmid DNA (phEPO) to produce long-term, therapeutic erythropoiesis. A single systemic injection of phEPO/ABP polyplex led to higher hematocrit levels over a 60-day period accompanied with reticulocytosis and high hEPO protein expression. In addition, we found that the distinct temporal and spatial distribution of phEPO/ABP polyplexes contributed to increased erythropoietic effects compared to those of traditional EPO therapies. Overall, our study suggests that ABP polymer-based gene therapy provides a promising clinical strategy to reach effective therapeutic levels of hEPO gene. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | NATURE PUBLISHING GROUP | - |
dc.title | Human Erythropoietin Gene Delivery Using an Arginine-Grafted Bioreducible Polymer System | - |
dc.type | Conference | - |
dc.contributor.affiliatedAuthor | Lee, Minhyung | - |
dc.identifier.scopusid | 2-s2.0-84863455207 | - |
dc.identifier.wosid | 000303484600497 | - |
dc.identifier.bibliographicCitation | 15th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), pp.S192 - S193 | - |
dc.relation.isPartOf | 15th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT) | - |
dc.relation.isPartOf | MOLECULAR THERAPY | - |
dc.citation.title | 15th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT) | - |
dc.citation.startPage | S192 | - |
dc.citation.endPage | S193 | - |
dc.citation.conferencePlace | US | - |
dc.citation.conferencePlace | Philadelphia, PA | - |
dc.citation.conferenceDate | 2012-05-16 | - |
dc.type.rims | CONF | - |
dc.description.journalClass | 1 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S1525001616325655?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.